Axsome Therapeutics Files 8-K
Ticker: AXSM · Form: 8-K · Filed: Jun 10, 2025 · CIK: 1579428
Sentiment: neutral
Topics: sec-filing, 8-k
Related Tickers: AXSM
TL;DR
AXSM filed an 8-K on 6/10/25, check for updates.
AI Summary
On June 10, 2025, Axsome Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's operations and financial status. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing signals an update from Axsome Therapeutics to the SEC, potentially containing important information for investors regarding the company's financial health or operational events.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific material information that would immediately impact risk.
Key Players & Entities
- Axsome Therapeutics, Inc. (company) — Registrant
- June 10, 2025 (date) — Date of earliest event reported
- 001-37635 (other) — Commission File Number
- 45-4241907 (other) — IRS Employer Identification No.
FAQ
What is the primary purpose of this 8-K filing by Axsome Therapeutics?
The filing is a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting "Other Events" and "Financial Statements and Exhibits" as of June 10, 2025.
When was the earliest event reported in this filing?
The earliest event reported is dated June 10, 2025.
What is Axsome Therapeutics' state of incorporation?
Axsome Therapeutics, Inc. is incorporated in Delaware.
What is the principal executive office address for Axsome Therapeutics?
The principal executive offices are located at One World Trade Center, 29th Floor, New York, New York, 10007.
What is the Commission File Number for Axsome Therapeutics?
The Commission File Number for Axsome Therapeutics is 001-37635.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 10, 2025 regarding Axsome Therapeutics, Inc. (AXSM).